Home
Search
Study Topics
Glossary
|
|
|
|
|
Sponsored by: |
University Hospital, Aker |
---|---|
Information provided by: | University Hospital, Aker |
ClinicalTrials.gov Identifier: | NCT00546039 |
The purpose of this study is to evaluate safety and mechanisms of possible chemopreventive effects of synthetic genistein (BONISTEIN™) in patients with localized prostate cancer undergoing laparoscopic radical prostatectomy.
Condition | Intervention | Phase |
---|---|---|
Prostatic Neoplasms |
Drug: Genistein Drug: Placebo |
Phase II |
Study Type: | Interventional |
Study Design: | Basic Science, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Parallel Assignment |
Official Title: | Effects of Synthetic Genistein Supplementation on Blood and Tissue Biomarkers in Patients With Localized Prostate Cancer |
Enrollment: | 47 |
Study Start Date: | April 2007 |
Estimated Study Completion Date: | January 2009 |
Primary Completion Date: | August 2008 (Final data collection date for primary outcome measure) |
Arms | Assigned Interventions |
---|---|
1: Active Comparator |
Drug: Genistein
Capsule, 30 mg, oral daily for 3 to 6 weeks
|
2: Placebo Comparator |
Drug: Placebo
Capsule
|
In Norway prostate cancer is the most frequently diagnosed cancer in the male and represents the second most common cause of cancer death among men.
Epidemiological studies have shown an association between decreased prostate cancer risk and increased soy consumption. Genistein is the dominating plasma and tissue isoflavone in soybean products, and it has been attributed several anti-cancer effects. BONISTEIN™ is a novel product, consisting of >99,5 % synthetic Genistein aglycone. Chemoprevention is the ability of certain molecules to inhibit (partially or totally) induction or progression of the disease. Our study population consists of men diagnosed with localized prostate cancer who have agreed to undergo radical prostatectomy. This provides adequate amount of benign, premalignant and malignant tissue for studying the effects of potential chemopreventive agents on biomarkers of cell growth and differentiation in the prostatic tissues with immunohistochemistry. Prostatic tissue cells will also be selected with Lacer Capture Microdissection (LCM) before analysis with semi-quantitative RT-PCR.
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Male |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Norway | |
Aker University Hospital | |
Oslo, Norway, 0514 |
Study Director: | Steinar J Karlsen, MD, PhD | Aker University Hospital, Oslo Urological Universityclinic |
Principal Investigator: | Bato Lazarevic, MD | Aker University Hospital, Oslo Urological Universityclinic |
Responsible Party: | Aker University Hospital ( Bato Lazarevic MD ) |
Study ID Numbers: | P2BV10 |
Study First Received: | October 17, 2007 |
Last Updated: | September 29, 2008 |
ClinicalTrials.gov Identifier: | NCT00546039 History of Changes |
Health Authority: | Norway: Norwegian Medicines Agency; Norway: The National Committees for Research Ethics in Norway; Norway: Data Inspectorate |
Prostate cancer Localized prostatectomy Laparoscopic prostatectomy |
Chemoprevention Genistein BONISTEIN™ |
Anticarcinogenic Agents Estrogens Genital Neoplasms, Male Prostatic Diseases Hormone Antagonists Hormones, Hormone Substitutes, and Hormone Antagonists Urogenital Neoplasms |
Genital Diseases, Male Hormones Protein Kinase Inhibitors Phytoestrogens Prostatic Neoplasms Genistein |
Anticarcinogenic Agents Estrogens Molecular Mechanisms of Pharmacological Action Genital Neoplasms, Male Prostatic Diseases Antineoplastic Agents Physiological Effects of Drugs Hormones, Hormone Substitutes, and Hormone Antagonists Enzyme Inhibitors Urogenital Neoplasms Genital Diseases, Male |
Protein Kinase Inhibitors Protective Agents Hormones Pharmacologic Actions Neoplasms Neoplasms by Site Estrogens, Non-Steroidal Therapeutic Uses Phytoestrogens Prostatic Neoplasms Genistein |